Type 2 diabetes (T2D) is a major driver of kidney failure, visual impairment, cardiovascular disease, and limb amputations, with significant and increasing clinical and economic burden. 1 Despite therapeutic advances, such as sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs2, many people living with T2D have above-target glycated haemoglobin HbA1c levels, 3 increasing the risk of long-term complications and early mortality. 4
No takes yet. Share an insight, caveat, or question.
Evans et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: